11 September 2017 - - US-based asthma diagnosis and management specialist Spirosure is exhibiting its CE-marked Fenom PRO Point-of-Care Breathalyzer at the the European Respiratory Society International Congress 2017 in Milan, Italy, the company said.
In recent years, non-invasive measurement and monitoring of the fraction of exhaled nitric oxide in exhaled breath has become established as the biomarker of asthma. The sensor based technology was licensed from Professor Prabir Dutta's innovative laboratories at The Ohio State University.
Spirosure's patent-protected fractional exhaled nitric oxide breath analyzer combines advanced materials with proprietary algorithms to provide high sensitivity in its ability to detect parts per billion (ppb) particle concentrations.
At the point of care, the patient exhales at a slow rate for 10 seconds to generate results in less than 30 seconds.
Fenom PRO is CE-marked for use in Europe by allergists, immunologists and pulmonologists. It is an investigational device in the United States that is limited for use to healthcare professionals in clinical trials to help manage asthma patients.
Spirosure focuses on the development and commercialization of novel breath analysis devices for application in diagnosis and management of asthma.